Two Companies Colloborate on a New Combined Solution to More Efficiently & Effectively Diagnose & Treat AFib & POAF

In An Effort to Improve Patient Outcomes

Peerbridge Health and Native Cardio Inc. recognize the postoperative challenges the 500,000+ cardiac surgery patients in the US face each year, with more than 20% developing postoperative atrial fibrillation (POAF). As a result, these companies are collaborating on a new combined solution to more efficiently and effectively diagnose and treat atrial fibrillation (AFib) and POAF, improving patient outcomes.

Without a way to predict which patients will develop POAF, every cardiac surgery patient is potentially at risk. In addition, there is no current standard of care for monitoring these patients after discharge for development of chronic AFib. Negative outcomes related to POAF include increased risk of stroke and death, extended length of stay in the hospital, hospital readmission following discharge, and risk of developing chronic atrial fibrillation. This results in billions of dollars wasted each year on poor health outcomes.

“POAF is the most frequent complication after cardiac surgery, and the incidence rate is on the rise,” said Dr. Joseph Pergolizzi, Founder and President of NativeCardio, Inc. “We’re happy to partner with Peerbridge to ensure cardiac patients have access to improved monitoring solutions that better address this serious health concern and restore their quality of life.”

Peerbridge Health and Native Cardio’s collaboration will elevate the importance of proactively monitoring and treating for POAF after a patient is discharged from the hospital following surgery. Physicians will be able to prescribe one unified solution to monitor patient progress and quickly treat POAF if complications occur. The powerful combination of the Peerbridge Cor™, a best-in-class wireless electrocardiogram (ECG) patch, and Native Cardio’s Rhythm MakerTM, a device that addresses POAF immediately by delivering an ultra-low shock to the patient’s heart, have the potential to negate poor patient outcomes, prevent hospital readmission, and better manage post-surgical patients.

“Currently, there is a lack of focus and coordination around the detection and treatment of POAF,” said Adrian Gilmore, CEO at Peerbridge Health. “Our collaboration with Native Cardio will ensure there is an integrated solution to address this challenge, while also improving patient outcomes and reducing costs for providers and payors.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”